Research programme: epidermolysis bullosa therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: epidermolysis bullosa therapeutics - InMed Pharmaceuticals

Alternative Names: INM-750

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator InMed Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 23 Dec 2016 Preclinical trials in Epidermolysis bullosa in Canada (Topical) before December 2016 (InMed pipeline, December 2016)
  • 04 Nov 2015 Pharmacodynamics data from preclinical studies in Epidermolysis bullosa released by InMed
  • 06 Aug 2015 InMed anticipates filing for orphan drug designation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top